Head And Neck Archives - IPN Delhi India

cetuximab injection

cetuximab injection
for intravenous use Initial U.S. Approval: 2004

cetuximab injection is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: Squamous Cell Carcinoma of the Head and Neck (SCCHN) & K-Ras Wild-type, EGFR-expressing Colorectal Cancer (CRC).

Facts about cetuximab injection

Approval Date: 2004
Proprietary Name: On Request
Active Ingredient(s): cetuximab injection
Dosage Forms And Strengths: Injection: 100 mg/50 mL (2 mg/mL) or 200 mg/100 mL (2 mg/mL) in a single-dose vial.
Company: Eli Lilly and Company
Current indications: Squamous Cell Carcinoma of the Head and Neck (SCCHN) & K-Ras Wild-type, EGFR-expressing Colorectal Cancer (CRC).
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import cetuximab injection” based on the information you provide.

Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India, including prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

Docetaxel Injection

Prostate, Breast Cancer, Gastrointestinal, Head And Neck, Lung

docetaxel Injection
for intravenous use Initial U.S. Approval: 1996

docetaxel Injection is a prescription anticancer medicine used to treat certain people with: • breast cancer • non-small cell lung cancer • prostate cancer • stomach cancer • head and neck cancer It is not known if TAXOTERE is effective in children. What are the ingredients in TAXOTERE? Active ingredient: docetaxel Inactive ingredients: polysorbate 80 and dehydrated alcohol solution.

Facts about docetaxel Injection

Approval Date: 1996
Proprietary Name: On Request
Active Ingredient(s): docetaxel Injection
Dosage Forms And Strengths: Injection: One-vial TAXOTERE: Single-dose vials 20 mg/mL and 80 mg/4 mL
Company: sanofi aventis
Current indications:
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import docetaxel Injection” based on the information you provide.

Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India, including prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

hydroxyurea capsules

Leukemia, Head And Neck

hydroxyurea capsules
for oral use Initial U.S. Approval: 1967

hydroxyurea capsules is an antimetabolite indicated for the treatment of: • Resistant chronic myeloid leukemia. • Locally advanced squamous cell carcinomas of the head and neck, (excluding lip) in combination with concurrent chemoradiation.

Facts about hydroxyurea capsules

Approval Date: 1967
Proprietary Name: On Request
Active Ingredient(s): hydroxyurea capsules
Dosage Forms And Strengths: Capsules: 500 mg
Company: Bristol-Myers Squibb
Current indications: chronic myeloid leukemia, head and neck
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import hydroxyurea capsules” based on the information you provide.

Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India, including prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

LOQTORZI (toripalimab-tpzi) injection

Head And Neck

LOQTORZI (toripalimab-tpzi) injection, for intravenous use Initial U.S. Approval: 2023

Loqtorzi is used to treat certain types of nasopharyngeal cancer (NPC) in adults. It may be prescribed as a first treatment when NPC has spread or come back. This means it must have spread or come back in other parts of your body near the throat.

Brand Name:	LOQTORZI
Generic Name:	toripalimab-tpzi
Strength:	Injection: 240 mg/6 mL (40 mg/mL) solution in a single-dose vial
Manufacturer:	Coherus BioSciences, Inc.
Approved By:	EMA, USFDA

Source Details: Patient Information

IPN, New Delhi can facilitate patient to import of “LOQTORZI (toripalimab-tpzi) injection” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for LOQTORZI (toripalimab-tpzi) injection price list or cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.

Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India, including prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

LUNSUMIO (mosunetuzumab-axgb) injection

Head And Neck

LUNSUMIO (mosunetuzumab-axgb) injection, for intravenous use Initial U.S. Approval: 2022

Lunsumio is a cancer medicine used to treat adults with follicular lymphoma that does not respond to (refractory) or has come back (relapsed) after at least two previous treatments. Lunsumio contains the active substance mosunetuzumab.

Brand Name:	LUNSUMIO
Generic Name:	mosunetuzumab-axgb
Strength:	Injection: • 1 mg/mL solution in a single-dose vial. • 30 mg/30 mL (1 mg/mL) solution in a single-dose vial.
Manufacturer:	Genentech
Approved By:	EMA, USFDA

Source Details: Patient Information

IPN, New Delhi can facilitate patient to import of “LUNSUMIO (mosunetuzumab-axgb) injection” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for LUNSUMIO (mosunetuzumab-axgb) injection price list or cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.

Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India, including prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

Nivolumab Injection

Lymphoma, Gastrointestinal, Head And Neck, Lung, Skin

nivolumab injection
for intravenous use Initial U.S. Approval: 2014

Nivolumab is used for the treatment of patients with Classic Hodgkin lymphoma, Colorectal cancer, Esophageal cancer or gastroesophageal junction adenocarcinoma, Gastric (stomach) cancer, gastroesophageal junction adenocarcinoma, or esophageal cancer, Malignant pleural mesothelioma, Melanoma, Non-small cell lung cancer, Renal cell carcinoma, Squamous cell carcinoma of the head and neck, Urothelial carcinoma.

Facts about nivolumab injection

Dosage Forms and strengths: Injection: 40 mg/4 mL, 100 mg/10 mL, and 240 mg/24 mL solution in a single dose vial.
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “nivolumab injection” based on the information you provide.

Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India, including prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

SOTYKTU (deucravacitinib) tablets

Head And Neck

SOTYKTU (deucravacitinib) tablets, for oral use Initial U.S. Approval: 2022

SOTYKTU is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

Brand Name:	SOTYKTU
Generic Name:	deucravacitinib
Strength:	Tablets: 6 mg
Manufacturer:	Boehringer Ingelheim Pharmaceuticals, Inc
Approved By:	EMA, USFDA

Source Details: Patient Information

IPN, New Delhi can facilitate patient to import of “SOTYKTU (deucravacitinib) tablets” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for SOTYKTU (deucravacitinib) tablets price list or cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.

Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India, including prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

ZORYVE (roflumilast) cream

Head And Neck

ZORYVE (roflumilast) cream, for topical use Initial U.S. Approval: 2011

Zoryve is used for plaque psoriasis and seborrheic dermatitis to reduce inflammation and symptoms when applied once daily anywhere on the body, including sensitive areas like face or skin folds and hairy areas. Zoryve cream and foam are steroid free and is well tolerated with very little stinging or burning

Brand Name:	ZORYVE
Generic Name:	roflumilast
Strength:	Cream, 0.3%: 3 mg of roflumilast per gram in 60-gram tubes.
Manufacturer:	Arcutis Biotherapeutics, Inc.
Approved By:	EMA, USFDA

Source Details: Patient Information

IPN, New Delhi can facilitate patient to import of “ZORYVE (roflumilast) cream” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for ZORYVE (roflumilast) cream price list or cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.

Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India, including prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

Head And Neck

cetuximab injection

cetuximab injection
for intravenous use Initial U.S. Approval: 2004

Facts about cetuximab injection

Access the best support services globally

Docetaxel Injection

docetaxel Injection
for intravenous use Initial U.S. Approval: 1996

Facts about docetaxel Injection

Access the best support services globally

hydroxyurea capsules

hydroxyurea capsules
for oral use Initial U.S. Approval: 1967

Facts about hydroxyurea capsules

Access the best support services globally

LOQTORZI (toripalimab-tpzi) injection

LOQTORZI (toripalimab-tpzi) injection, for intravenous use Initial U.S. Approval: 2023

LUNSUMIO (mosunetuzumab-axgb) injection

LUNSUMIO (mosunetuzumab-axgb) injection, for intravenous use Initial U.S. Approval: 2022

Nivolumab Injection

nivolumab injection
for intravenous use Initial U.S. Approval: 2014

Facts about nivolumab injection

Access the best support services globally

SOTYKTU (deucravacitinib) tablets

SOTYKTU (deucravacitinib) tablets, for oral use Initial U.S. Approval: 2022

ZORYVE (roflumilast) cream

ZORYVE (roflumilast) cream, for topical use Initial U.S. Approval: 2011

Contact Info

Query Form For Medications

Indian Pharma Network (IPN), New Delhi. India

Company

Drugs Approved for

Gastroenterology

Hematology

Drugs Approved For

Head And Neck

cetuximab injection for intravenous use Initial U.S. Approval: 2004

Facts about cetuximab injection

Access the best support services globally

docetaxel Injection for intravenous use Initial U.S. Approval: 1996

Facts about docetaxel Injection

Access the best support services globally

hydroxyurea capsules for oral use Initial U.S. Approval: 1967

Facts about hydroxyurea capsules

Access the best support services globally

LOQTORZI (toripalimab-tpzi) injection, for intravenous use Initial U.S. Approval: 2023

LUNSUMIO (mosunetuzumab-axgb) injection, for intravenous use Initial U.S. Approval: 2022

nivolumab injection for intravenous use Initial U.S. Approval: 2014

Facts about nivolumab injection

Access the best support services globally

SOTYKTU (deucravacitinib) tablets, for oral use Initial U.S. Approval: 2022

ZORYVE (roflumilast) cream, for topical use Initial U.S. Approval: 2011

Contact Info

Query Form For Medications

Indian Pharma Network (IPN), New Delhi. India

cetuximab injection
for intravenous use Initial U.S. Approval: 2004

docetaxel Injection
for intravenous use Initial U.S. Approval: 1996

hydroxyurea capsules
for oral use Initial U.S. Approval: 1967

nivolumab injection
for intravenous use Initial U.S. Approval: 2014